Cerus Promotes COO Vivek Jayaraman to CEO as Greenman Steps Up to Executive Chairman
Event summary
- Vivek Jayaraman, Cerus’ COO since 2020, will become CEO on July 1, 2026.
- William 'Obi' Greenman transitions to executive chairman after 15 years as CEO.
- Jayaraman led revenue growth from $40M to over $200M annually during his tenure.
- Greenman oversaw Cerus’ transformation from preclinical development to global commercial enterprise.
The big picture
Cerus’ leadership transition comes as the company seeks to solidify its position in transfusion medicine, with a focus on expanding the reach of its INTERCEPT Blood System. The shift from Greenman’s long tenure to Jayaraman’s operational expertise marks a strategic pivot towards scaling commercial operations globally. Cerus aims to leverage its robust innovation pipeline and financial foundation to maintain market leadership.
What we're watching
- Leadership Transition
- How Vivek Jayaraman will navigate Cerus’ next phase of growth, focusing on global expansion and patient access.
- Market Positioning
- Whether Cerus can sustain its leadership in transfusion medicine amid regulatory reviews and clinical developments.
- Regulatory Dynamics
- The pace at which the INTERCEPT red blood cell system gains approvals in Europe and the U.S.
Related topics